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Abstract
Machado-Joseph disease (MJD) or spinocerebellar ataxia type 3 (SCA3) is an autosomal dominant neurodegenerative disorder
caused by expansion of the polyglutamine domain of the ataxin-3 (ATX3) protein. MJD/SCA3 is the most frequent autosomal
dominant ataxia in many countries. The mechanism underlying MJD/SCA3 is thought to be mainly related to protein misfolding
and aggregation leading to neuronal dysfunction followed by cell death. Currently, there are no effective treatments for patients
with MJD/SCA3. Here, we report on the potential use of lithium carbonate and coenzyme Q10 to reduce cell death caused by
the expanded ATX3 in cell culture. Cell viability and apoptosis were evaluated by MTT assay and by flow cytometry after stain-
ing with annexin V-FITC/propidium iodide. Treatment with lithium carbonate and coenzyme Q10 led to a significant increase
in viability of cells expressing expanded ATX3 (Q84). In addition, we found that the increase in cell viability resulted from a
significant reduction in the proportion of apoptotic cells. Furthermore, there was a significant change in the expanded ATX3
monomer/aggregate ratio after lithium carbonate and coenzyme Q10 treatment, with an increase in the monomer fraction and
decrease in aggregates. The safety and tolerance of both drugs are well established; thus, our results indicate that lithium
carbonate and coenzyme Q10 are good candidates for further in vivo therapeutic trials.
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Introduction
Machado-Joseph disease (MJD), also known as spino-
cerebellar ataxia type 3 (SCA3), is an autosomal domi-
nantly inherited neurodegenerative disorder. It is caused
by CAG triplet repeat expansions that encode an expanded
polyglutamine (polyQ) tract in the disease-related protein,
ataxin-3 (ATX3). Other members of this group include
Huntington’s disease, SCA 1, 2, 6, 7, and 17, dentatorubral-
pallidoluysian atrophy, and spinobulbar muscular atrophy.
MJD/SCA3 is the most frequent type of autosomal domi-
nant spinocerebellar ataxia in many countries, represent-
ing 15 to 45% of all SCAs (1,2). Clinical manifestations
include ataxia, ophthalmoplegia, pyramidal signs, basal
ganglia symptoms, and peripheral neuropathy (3,4).
MJD/SCA3 is characterized by an expansion of the
polyQ tract near the C-terminus of the MJD-1 gene pro-
duct, ATX3 (5). Expanded polyQ tracts likely lead to pro-
tein misfolding, neuronal dysfunction and death. Although
ATX3 is ubiquitously expressed, degeneration occurs pre-
ferentially in brain regions such as the substantia nigra,
motor cranial nuclei, and dentate nucleus of the cere-
bellum (4). An abnormal accumulation of misfolded
expanded ATX3, along with molecular chaperones, tran-
scription factors or co-activators, and the components of
the proteasome, forms highly ubiquitinated neuronal inclu-
sions, which constitute a pathological hallmark of MJD/
SCA3, as in other polyglutamine diseases (5,6).
Expanded ATX3 tends to accumulate in the cell nucleus
and several studies suggest that these accumulating
proteins cause transcription dysregulation through aber-
rant protein-protein interactions (1). It has been demon-
strated that ATX3 sequesters the basal transcription factor
TATA-binding protein and the transcriptional co-activator
CREB-binding protein in the nuclear inclusions in cell-based
models and in disease tissue. Furthermore, microarray
gene expression profiling in MJD/SCA3 transgenic mice
revealed that expanded ATX3 may cause cerebellar dys-
function and ataxia by disrupting the normal pattern of
gene transcription (7). To date, there is no specific treat-
ment for the neurodegeneration affecting patients with
MJD/SCA3 (8).
Here, we report on the potential use of lithium car-
bonate and coenzyme Q10 (CoQ10) to reduce the cell
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death caused by the expanded ATX3 in a cultured cell
model. We focused on two substances that are nontoxic
and can be administered safely to patients.
Material and Methods
Cell culture, transfection and drug treatment
PC12 cells were grown in Dulbecco’s modified Eagle’s
medium (DMEM, Gibco, USA) supplemented with 100 mg/mL
penicillin/streptomycin, 2 mM L-glutamine, 10% fetal bovine
serum and maintained at 37°C, 5% CO2 in a humidified
incubator.
The expression vector pcDNA encoding human
full-length ATX3 was used for transfection. Constructs of
normal ATX3 (pcDNA3-myc-ATX3-Q28) and expanded
ATX3 (pcDNA3-myc-ATX3-Q84) were previously reported (7),
and were kindly provided by Dr. Henry Paulson, University
of Michigan, Ann Arbor, MI, USA.
For transient transfections, cells were seeded on
6-well plates and grown to 60–80% confluence for 16 h.
For each well, cells were exposed for 5 h to a mixture of
10 mL LipofectAMINE 2000 Reagentt (Invitrogen, USA)
and 2 mg of plasmid DNA in OptiMEM (Gibco, USA).
Then, the culture medium was replaced by complete
medium containing distinct drugs. Cells were incubated
for another 48 h and examined. Drug treatments included
2.5, 5 or 7.5 mM lithium carbonate (Acros Organicst,
Belgium) and 10, 30, or 90 mM coenzyme Q10 (Solgart,
USA).
Cell viability and apoptosis
Cell viability was evaluated by the MTT, 3-(4,5-dimethyl-
thiazole-2-yl)-2,5-diphenyl tetrazolium assay. After 48 h of
drug treatment, the medium was replaced, MTT was added
to the DMEM (0.3 mg/mL) followed by a 4-h incubation.
Next, cells were washed with PBS, dye crystals were
dissolved in DMSO and the absorbance measured at
570 nm.
Apoptotic cells were detected using the ApoTargett
Annexin-V FITC Apoptosis Kit (Invitrogen), which employs
a fluorescein-labeled Annexin-V (Annexin-V FITC) in con-
cert with propidium iodide (PI), following manufacturer’s
recommendation. Samples were analyzed on a FACS-
calibur flow cytometer (Becton Dickinson, USA). For each
sample, a minimum of 10,000 events were collected and
analyzed using CELLQuest software (Becton Dickinson).
The PI results were used to exclude necrotic cells from the
evaluation of apoptosis.
Western blot
Protein was extracted with TRIzol reagent (Invitrogen,
USA). Samples were run on discontinuous 10% SDS-
polyacrylamide gels (PAGE) and both the stacking and
separating portions of the gel were blotted onto Hybond-C
Extra nitrocellulose membranes (GE Healthcare, USA).
Blots were incubated with affinity-purified ATX3 antiserum
(1:1,000, kindly provided by Dr. H. Paulson), followed by
alkaline phosphatase-conjugated goat anti-rabbit IgG
(1:20,000, Sigma, USA).
Aggregates are insoluble in SDS-PAGE and, therefore,
remain in the stacking portion of the gel. ATX3 monomer/
aggregate ratios were calculated based on band densito-
metry using ImageJ software.
Statistical analysis
Results are reported as the means±SE value of
3 experiments. The Kruskal-Wallis test followed by the
Student-Newman-Keuls test was performed using Bio-
Estat 5.0 software (Brazil) to determine whether differ-
ences were statistically significant (Po0.05).
Results
Transient expression of full-length expanded ATX3
(Q84) induced intracellular aggregate formation and cell
death when compared with cells expressing constructs
with normal ATX3 (Q28), as previously demonstrated
(7,9–12). We evaluated the effects of two drugs on cell
cultures expressing ATX3 constructs: lithium carbonate
and CoQ10. Drug effects were initially evaluated in cell
cultures transfected with normal ATX3 (Q28) construct for
both drugs in different doses. We used this experiment as
a control for any possible unspecific effects of the drugs
on cell viability and proliferation. As expected, drug
treatment did not alter viability of cells expressing normal
ATX3 (Q28) (Figure 1).
Lithium carbonate treatment
Cells were treated with three concentrations of lithium
carbonate, and cell viability was initially evaluated by
the MTT assay. In cell cultures expressing the expanded
ATX3 (Q84), we observed a relative increase in cell via-
bility after treatment with a 5 mM initial lithium carbonate
Figure 1. PC12 cells transfected with full-length normal ATX3
(Q28) and treated with different concentrations of lithium carbo-
nate or coenzyme Q10 (CoQ10). Drug effects on cell viability
were analyzed after 48 h. Relative cell viability was measured by
the MTT assay. All experiments were performed in triplicate and
data are reported as means±SE.
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concentration. The effect was dose dependent: a 17 and
21% increase in cell viability was observed after treat-
ment with 5 and 7.5 mM lithium carbonate, respectively
(P=0.0117 and P=0.0046; Figure 2A). In contrast, no
effect on cell viability was observed with the lowest
concentration of lithium carbonate tested (2.5 mM). These
results were confirmed by flow cytometry analysis after
Annexin V/PI double staining. Although in cell cultures
expressing ATX3-Q84 there were more apoptotic cells
(compared to ATX3-Q28 cells), lithium treatment signifi-
cantly reduced the percentage of apoptotic cells from
24 to 13.7% as demonstrated by flow cytometry analysis
(P=0.0495; Figure 2B).
Western blot was chosen to evaluate a possible modi-
fication in the ATX3 monomer/aggregate ratio because
ATX3-Q84 forms insoluble high molecular weight com-
plexes at the top of stacking SDS gels. Indeed, we found
that the monomer/aggregate ratio changed significantly
after lithium treatment (P=0.0495), with an increase in
the monomer fraction and decrease in the aggregates
(Figure 2C and D).
Coenzyme Q10 treatment (CoQ10)
Relative cell viability, measured by the MTT assay,
increased by 14% after 10 mM of CoQ10 treatment (P=
0.0357; Figure 3A). A greater concentration of CoQ10
(30 mM) increased cell viability by 11%, but not signifi-
cantly (P=0.715; Figure 3A). In addition, we observed a
10% reduction in apoptotic cells by flow cytometry
analysis after Annexin V/PI double staining (P=0.0339;
Figure 3B). Furthermore, CoQ10 treatment significantly
changed the ATX3-Q84 monomer/aggregate ratio (P=
0.0495), with a relative increase in the monomer fraction
and decrease in the aggregates (Figure 3C and 3D).
Discussion
Strategies that decrease the cytotoxicity associated
with expanded ATX3 in vitro models represent important
therapeutic approaches. The activation of mitochondrial
apoptotic pathways followed by increased mitochondrial
DNA damage has been reported in cellular models of MJD,
establishing a mitochondrial role in MJD pathology (13).
Figure 2. PC12 cells transfected with full-length expanded ATX3 (Q84), treated with different concentrations of lithium carbonate
and analyzed after 48 h. A, Relative cell viability by the MTT assay. B, Percentage of apoptotic cells analyzed by flow cytometry after
Annexin V and propidium iodide staining. C, ATX3-Q84 monomer/aggregate ratio analyzed by western blotting. D, Band densitometry
was calculated with ImageJ software, and data of monomer/aggregate ratio were plotted in a graph. All experiments were performed in
triplicates and data are reported as means±SE. *Po0.05, Kruskal-Wallis test.
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However, we did not analyze the effects on mitochondrial
function upon treatment with coQ10 and lithium in this
phase of our study, but rather focused on the potential
effects of these two drugs on ATX3-Q84-induced cell death.
One important issue that should be addressed when
using the strategy we describe is the possibility that
the results of increased cell viability be confounded by
increased cell proliferation induced by the drugs tested.
We addressed this issue by using cell cultures expressing
ATX3-Q28 (normal ATX3 constructs) as controls and
demonstrating that there was no variation in baseline
measures in any of the experiments performed. These
results indicate that the drugs did not induce cell pro-
liferation because there was no variation in cell viability in
cultures expressing ATX3-Q28 when subjected to the
different treatments.
Lithium carbonate treatment
Lithium carbonate significantly increased cell viability
in 17 to 21% of cells expressing ATX3-Q84, as measured
by the MTT assay, depending on the dose used. In addi-
tion, flow cytometry allowed us to specifically evaluate the
percentage of apoptotic cells stained only for Annexin V.
In cell cultures expressing ATX3-Q84, we found a 10%
reduction in apoptotic cells after lithium treatment.
Lithium carbonate has been reported to have bene-
ficial effects in different models of Huntington’s disease
(HD) and SCA1. Lithium reduced the toxicity induced by
cells expressing exon 1 of the HD gene with 74 CAGs
in neuronal and non-neuronal cell lines (14). Chronic
treatment with lithium caused a significant improvement in
the rotarod performance of HD transgenic mice (R6/2 line)
expressing exon 1 of the HD gene with approximately 150
CAGs (15). Furthermore, lithium treatment of SCA1 animal
models expressing full-length ATX1 with 154 glutamines
improved motor dysfunction and cognitive impairment (16).
On the other hand, a recent study showed that the treat-
ment of a MJD transgenic mouse model (CMVMJD135) with
a conjugation of lithium chloride and CCI-779 (Temsirolimus)
at a nontoxic concentration known to induce autophagy was
deleterious to both wild-type and transgenic animals (17).
In another study performed by this same group, results that
did not support lithium chronic treatment as a promising
strategy for the treatment of MJD were reported (18).
Figure 3. PC12 cells transfected with full-length expanded ATX3 (Q84), treated with different concentrations of coenzyme Q10 (CoQ10)
and analyzed after 48 h. A, Relative cell viability was measured by the MTT assay. B, Percentage of apoptotic cells analyzed by flow
cytometry after Annexin V and propidium iodide staining. C, ATX3-Q84 monomer/aggregate ratio analyzed by western blotting. D, Band
densitometry was calculated with ImageJ software and the data of monomer/aggregate ratio were plotted in a graph. All experiments
were performed in triplicate and data are reported as means±SE. *Po0.05, Kruskal-Wallis test.
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We found a significant change in the ratio of monomer/
aggregate of ATX3-Q84 after lithium treatment, with an
increase in the monomer fraction and decrease in the
aggregates. Lithium was reported to reduce the proportion
of cells with aggregates in a HD cell model (14). Although
aggregates represent a pathological hallmark of poly-
glutamine diseases, their association with neurodegen-
eration and precise role in disease pathogenesis remain
unclear. Aggregate frequency and cytotoxicity induced
by truncated expanded ATX3 were reduced after cell
treatment with chemical chaperones (19). In addition, on
immunoblot analyses, there was a decrease in insoluble
complexes in the stacking gel with an increase in the
monomeric protein; this was also reported for transgenic
flies co-expressing truncated expanded ATX3 and mole-
cular chaperones (20).
Lithium neuroprotective effects have been previously
documented; however, its mechanism of action has not been
fully established. Lithium may act through expression modu-
lation of several genes such as TP53, Bax, Bcl-2 and GSK-3
(21,22). Over-expression of glycogen synthase kinase-3
(GSK-3) potentiates apoptosis in neuroblastoma cells,
while GSK-3 inhibitors, such as lithium, protect cells against
apoptosis (14,22,23). Since expanded ATX3 may disrupt
normal gene transcription patterns (7), lithium may act as a
protective factor by modulating gene expression.
The reduction in cell death induced by treatment with
lithium carbonate in cells expressing expanded ATX3
demonstrated in our study is further evidence of the
therapeutic potential of lithium in polyglutamine diseases,
as demonstrated in HD and SCA1 models. Furthermore,
since this drug has been used in patients for over
50 years, its therapeutic potential and toxic effects are well
known (24). However, one should be aware that among
the side effects of lithium treatment are tremors and lack
of coordination, especially when the dose is not well
monitored (25). These side effects may be an additional
risk in patients with cerebellar dysfunction; therefore,
Watase et al. (16) evaluated the occurrence of tremors in
mice during treatment with lithium and found no increase
of these events as compared to untreated animals.
Recent studies reporting trials with lithium treatment
in patients with MJD/SCA3 had somewhat limited results
(26,27), but there were some suggestions that lithium
treatment could be beneficial to patients in the early
stages of the disease and to specific symptoms such as
cerebellar dysfunction (27).
Coenzyme Q10 treatment
Our results showed that CoQ10 treatment protected
against ATX3-Q84-induced death in PC12 cells, increas-
ing cell viability. There was an 11% reduction in apoptotic
cells, with no induction of cell proliferation as a confounding
factor. In addition, we also found a significant change in the
ratio of monomer/aggregate of ATX3-Q84 after CoQ10 treat-
ment. Aggregate reduction was also observed in transgenic
mouse models for HD treated with CoQ10 (28,29). In a toler-
ance study, CoQ10 was well tolerated and safe in patients at
doses as high as 3000 mg/day, but the plasma CoQ10 level
reaches a plateau at the dose of 2,400 mg/day (30).
There is some evidence of mitochondrial dysfunction
and bioenergetic abnormalities in the pathogenesis of
neurodegenerative diseases (31). Analyses of HD post
mortem brain tissues showed impaired oxidative phos-
phorylation enzyme activity, decreased mitochondrial com-
plex activity, and increased oxidative damage product
8-hydroxydeoxyguanosine (32). Additionally, a MJD/SCA3
in vitro model demonstrated that expanded ATX3 impairs
the cell’s ability to respond to stress, alters antioxidant
enzyme activities, and promotes mitochondrial DNA damage,
which may lead to mitochondrial dysfunction (13). Thus,
compounds that enhance cellular and mitochondrial bio-
energetics are interesting candidates for treating MJD/
SCA3. In this work, we studied CoQ10, a cofactor of the
electron transport chain and a potent antioxidant (33).
Several in vitro models have previously demonstrated
the neuroprotective effects of CoQ10. In neuronal models
of oxidative stress, CoQ10 pretreatment preserves mito-
chondrial membrane potential and reduces the generation
of reactive oxygen species (34). In cultured neurons from
HD transgenic mice, cell death is reduced after CoQ10
treatment (35). Other studies showed that oral adminis-
tration of CoQ10 in a transgenic HD mouse model extends
survival, improves motor performance and reduces brain
atrophy (28,29,36).
The elevated levels of lactate in the cerebral cortex
and basal ganglia of HD patients were reduced after
CoQ10 treatment (37). These results suggest that CoQ10
has metabolic effects in cerebral tissue. The Huntington’s
Study Group (38) performed the CARE-HD trial using
CoQ10 alone or in combination with remacemide and
demonstrated the safety and tolerance of these drugs.
In addition, CoQ10 reduced the trend toward cognitive
and functional decline. Moreover, several clinical trials
for Parkinson’s disease, Alzheimer disease, amyotrophic
lateral sclerosis and Friedreich ataxia demonstrated the
potential neuroprotective effects of CoQ10 (39).
Besides being a natural compound, safe and well
tolerated with few side effects (30,40), CoQ10 is able to
cross the brain barrier, as demonstrated in animal studies.
CoQ10 oral administration in HD mice increased the levels
of CoQ10 in the brain of these animals (29). Thus, our
results together with evidence from the literature point to
the potential of this compound for treating patients with
MJD/SCA3. To our knowledge, there have been no clinical
trials with CoQ10 in patients with MJD/SCA3.
In conclusion, we demonstrated that lithium carbonate
and CoQ10 reduced apoptosis induced by expanded
ATX3 (Q84). Currently, there are no effective treatments
for patients with MJD/SCA3, hence, the importance of
studying compounds capable of reducing the disease’s
cytotoxic effects. Safety and tolerance of both drugs are
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well established; thus our results indicate that lithium
carbonate and CoQ10 can be putative candidates for
further in vivo therapeutic trials.
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